GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viridian Therapeutics Inc (LTS:0K1R) » Definitions » NonCurrent Deferred Liabilities

Viridian Therapeutics (LTS:0K1R) NonCurrent Deferred Liabilities : $0.57 Mil (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Viridian Therapeutics NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Viridian Therapeutics's non-current deferred liabilities for the quarter that ended in Dec. 2023 was $0.57 Mil.

Viridian Therapeutics NonCurrent Deferred Liabilities Historical Data

The historical data trend for Viridian Therapeutics's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viridian Therapeutics NonCurrent Deferred Liabilities Chart

Viridian Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 1.15 0.86 0.57

Viridian Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.86 0.79 0.72 0.65 0.57

Viridian Therapeutics NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Viridian Therapeutics's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Viridian Therapeutics (LTS:0K1R) Business Description

Traded in Other Exchanges
Address
221 Crescent Street, Suite 401, Waltham, MA, USA, 02453
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.

Viridian Therapeutics (LTS:0K1R) Headlines

No Headlines